studying-triple-negative-breast-cancer-using-orthotopic-breast-cancer

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited therapeutic options. When compared to patients with less ...

National Cancer Institute at Frederick

Nitroxyl (HNO) donors have been shown to elicit a variety of pharmacological responses, ranging from tumoricidal effects to treatment of heart failure. Isopropylamine-based diazeniumdiolates have been shown to produce HNO on decomposition under physiological conditions. Herein, we report the synthesis and HNO release profiles of primary alicyclic amine-based diazeniumdiolates. These compounds extend the range of known diazeniumdiolate-based HNO donors. Acetoxymethyl ester-protected diazeniumdiolates were also synthesized to improve purification and cellular uptake. The acetoxymethyl derivative of cyclopentylamine diazeniumdiolate not only showed higher cytotoxicity toward cancer cells as compared to the parent anion but was also effective in combination with tamoxifen for targeting estrogen receptor α-negative breast cancer cells.

Debashree Basudhar

Molecular Mechanism Section,
Cancer and Inflammation Program,
Center for Cancer Research,
Molecular Mechanism Section, Cancer and Inflammation Program, Center for Cancer Research

National Cancer Institute at Frederick

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Debashree Basudhar

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}Molecular Mechanism Section,Cancer and Inflammation Program,Center for Cancer Research,Molecular Mechanism Section, Cancer and Inflammation Program, Center for Cancer Research

National Cancer Institute at Frederick

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Molecular Mechanism Section,
Cancer and Inflammation Program,
Center for Cancer Research,
Molecular Mechanism Section, Cancer and Inflammation Program, Center for Cancer Research